GlassScriptPhysician profile
Jiho Choi
NPI 1225149859
$5,105.36
in general payments reported to CMS, 2019-2025
26 companies · $424 in 2025
The $424 reported for 2025 was more than what 79% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $579 · 2021: $988 · 2022: $868 · 2023: $748 · 2024: $487 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $1,268.31 | 2021-2024 | Tirosint, Licart, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $548.77 | 2019-2020 | |
| Novo Nordisk INC | $385.91 | 2020-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $369.09 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $306.40 | 2019-2023 | Xarelto |
| Scilex Pharmaceuticals INC. | $294.73 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $265.18 | 2024-2025 | Gemtesa |
| Amgen INC. | $250.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $196.99 | 2021-2022 | |
| Lilly USA, LLC | $179.17 | 2021-2025 | Mounjaro, Amyvid, Zepbound |
| Astellas Pharma US INC | $177.88 | 2019-2025 | Myrbetriq, Veozah |
| Abbvie INC. | $164.10 | 2022-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $142.71 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $107.60 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $77.73 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.63 | 2022-2024 | Jardiance |
| Hikma Pharmaceuticals USA | $62.28 | 2021 | |
| Eyevance Pharmaceuticals LLC | $62.28 | 2021 | |
| Radius Health, INC. | $34.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.14 | 2022 | |
| Vivus LLC | $21.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.14 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $19.86 | 2023 | |
| Horizon Therapeutics Plc | $19.71 | 2021 | |
| Esperion Therapeutics, INC. | $17.11 | 2021 | |
| Evoke Pharma, INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiho Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.